Upregulation of MUC1 and CD44 has been shown to be associated with resistance to the highly used IMiD, lenalidomide (LEN), in MM [48] and the ability of RUX to downregulate their expression, potentially serving as a means to overcome resistance, is an attractive benefit of this JAK inhibitor. Here, CD44 is linked to Miyoshi myopathy.